Skip to main content

LunairCF is a clinical trial for adults living with Cystic Fibrosis who are not eligible for or not taking CFTR modulators.

LunairCF is studying the medical benefit of using mRNA with Arcturus’ LUNAR® technology to help improve the lung health of participants who have CF.

LunairCF is an international clinical trial.

For the most up-to-date information about sites and contact information, please contact us at [email protected]

Purpose

We are assessing the safety and tolerability of repeated doses of ARCT-032 over 4 weeks in Groups 1-3 and over 12 weeks in Group 4. The study will include people with CF, with mutations that do not respond to CFTR modulators and those who did not tolerate or respond to CFTR modulators in the past. We also will assess the impact of ARCT-032 on lung function (spirometry), quality of life, and chest imaging studies (CT scans) that may show structural changes in the lungs.

Eligibility

  • Adults 18 years of age or older with confirmed diagnosis of Cystic Fibrosis
  • Not eligible for CFTR modulators therapy or not taking CFTR modulators
  • Forced expiratory volume in 1 second (FEV1) between 45% to 90% of predicted values at screening
  • Other requirements may apply

Treatment

Study participants will receive doses of LunairCF via inhalation for 4 weeks in Groups 1-3 and for 12 weeks in Group 4.

Duration

There are 8 study visits and 2 follow-up phone calls over a 20-week period (including a screening visit) for Groups 1-3, and 13 study visits (including 2 screening visits) over a 28-week period for Group 4.

Location

Approximately 20+ sites in the US and the Middle East.

For additional information about this study such as eligibility criteria and participating sites, visit clinicaltrials.gov (NCT06747858) or contact us directly [email protected].

Those who qualify will receive all study-related laboratory tests, medical exams, and travel at no cost.